Crescent Biopharma, Inc. CBIO
Crescent Biopharma, Inc. (Nasdaq: CBIO) is an oncology drug developer. Its lead program, CR-001 (SKB118), is in Phase 1 for Solid tumors incl. NSCLC (PD-1 x VEGF bispecific antibody). Its next catalyst on record is CR-002: Crescent is on track to initiate the global Phase 1/2 APOLLO trial of CR-002 in the fourth quarter of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CR-002 — Crescent is on track to initiate the global Phase 1/2 APOLLO trial of CR-002 in the fourth quarter of 2026. (Q4 2026). 28 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CR-001 + sac-TMT (Kelun-sponsored China Ph2) | NSCLC | antibody | Phase 2 |
| CR-001 (PD-1 x VEGF bispecific; ASCEND global Ph1/2) | Up to eight solid tumor types incl. NSCLC | antibody | Phase 1 |
| CR-003 (SKB105, ITGB6 ADC; China Ph1/2 run by Kelun) | Solid tumors | biologic-other | Phase 1 |
| CR-002 (PD-L1 ADC) | Solid tumors | biologic-other | Pre-clinical |
Recent results and decisions
- Oct 15, 2026started Enrollment has commenced in the standard of care chemotherapy combination expansion cohorts of the ASCEND trial for CR-001.
Enrollment has also commenced in the standard of care chemotherapy combination expansion cohorts of ASCEND.
Filing - Oct 15, 2026started Crescent commenced enrollment in standard of care chemotherapy combination expansion cohorts of CR-001 ASCEND trial across multiple tumor types.
Enrollment has also commenced in the standard of care chemotherapy combination expansion cohorts of ASCEND.
Filing - Oct 15, 2026accepted CR-002 received IND allowance from FDA to proceed with clinical development.
In October 2026, the Company's topoisomerase inhibitor ADC targeting PD-L1, CR-002, received allowance to proceed under an Investigational New Drug Application from the U.S. Food and Drug Administration.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.